. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2374–2381. doi: 10.1158/1535-7163.MCT-15-0121

Table 2.

Baseline characteristics and primary outcome measurements of the tested cohorts

	Training set further-line cetuximab N= 108	FIRE-3 FOLFIRI + cetuximab N= 153	FIRE-3 FOLFIRI + bevacizumab N= 168
median age, years (range)	64 (35-110)	64 (42-76)	65 (31-76)

gender
female	39.8%	24.8%	30.4%
male	60.2%	75.2%	69.6%

ECOG PS (%)
0	62.1%	53.6%	55.4%
1	37.9%	45.8%	43.5%
2		0.7%	1.2%

localization
midgut	N/A	16.3%	17.9%
hindgut		80.4%	78.5%
unknown		3.3%	3.6%

ORR	20%	77.7%	60.7%

PFS (months) (95% CI)	3.7 (2.8 – 4.6)	10.5 (9.1 – 12.0)	11.3 (10.1 – 12.5)

OS (months) (95% CI)	10.5 (7.7 – 13.3)	36.4 (27.7 – 45.1)	27.7 (24.4 – 31.0)

Legend: ORR = objective response rate; PFS = progression-free survival, OS = overall survival, 95% CI = 95% confidence interval